Login / Signup

Immunomodulation for early-onset haemolytic disease of the fetus/newborn: Can we delay the need for intrauterine transfusions?

Kenneth Jpseph Moise
Published in: British journal of haematology (2022)
When cases of severe fetal anaemia due to maternal red-cell alloimmunization present in the early second trimester, standard treatment with intrauterine transfusion often results in fetal loss. The report by Vlachodimitropoulou et al. offers new insight into the use of maternal intravenous immune globulin to delay the need for intrauterine transfusion. Performing these procedures at a later gestational age increases the likelihood of technical success and subsequent perinatal survival. Commentary on: Vlachodimitropoulou et al. Intravenous immune globulin in the management of severe early onset of red cell alloimmunization. Br J Haematol 2022 (Online ahead of print). https://doi.org/10.1111/bjh.18449.
Keyphrases
  • early onset
  • gestational age
  • birth weight
  • late onset
  • sickle cell disease
  • preterm birth
  • single cell
  • pregnancy outcomes
  • cardiac surgery
  • cell therapy
  • high dose
  • pregnant women
  • healthcare